PROTAC Technology Advances Toward Phase III Trials in Cancer Treatment

Proteolysis-targeting chimeras (PROTACs) are entering advanced clinical trials for cancer treatment, marking a shift from experimental technology to potential therapeutic reality. The first PROTAC candidates are now being evaluated in Phase III studies, representing a fundamental change from blocking protein function to physically eliminating disease-causing proteins.

PROTACs are heterobifunctional molecules composed of three key elements: a ligand that binds the target protein (protein of interest, POI), a ligand that recruits an E3 ubiquitin ligase, and a chemical linker connecting the two. The spatial proximity causes the target protein to be ubiquitinated and subsequently degraded by the cellular 26S proteasome. This catalytic mechanism of action enables a single PROTAC molecule to tag numerous target proteins in succession, resulting in high efficiency at lower doses.

Unlike traditional small-molecule drugs, which typically act by temporarily blocking the activity of a protein, PROTACs function by physically removing the target protein from the cell. Upon formation of the ternary complex, PROTACs promote the transfer of ubiquitin molecules to lysine residues on the target protein, resulting in polyubiquitination. The polyubiquitinated POIs are subsequently recognized by the 26S proteasome, where ubiquitin chains are removed and the target proteins are efficiently degraded.

A key advantage over traditional inhibitors is the ability to overcome resistance. Tumor cells often develop mutations in the active site that prevent inhibitors from binding. However, since PROTACs do not necessarily have to bind to the catalytic site but can use any accessible pocket on the protein surface, they open up new therapeutic windows. This strategy provides access to target proteins that were previously considered "undruggable."

Vepdegestrant (ARV-471), an orally available estrogen receptor (ER) degrader, is currently being investigated in a large-scale Phase III study (VERITAC-2) in patients with ER-positive/HER2-negative locally advanced or metastatic breast cancer. Phase I/II data have already shown a significant reduction in ER levels in tumor tissue and a clinical benefit rate that potentially eclipses conventional fulvestrant therapies.

Bavdegalamide (ARV-110) targets the androgen receptor (AR). Following promising results in patients with metastatic castration-resistant prostate cancer (mCRPC) who had already received multiple prior therapies, the developers are paving the way for broader clinical applications in advanced stages.

The momentum in PROTAC development is being driven by well-funded international consortia. In the US and Asia, companies such as Arvinas, Pfizer, and Roche are collaborating intensively with university hospitals to optimize the pharmacokinetics of the often quite large-molecular chimeras. A particular focus is on overcoming the blood-brain barrier for the treatment of CNS metastases. Projects such as the European Research Council (ERC)-funded project on the "Design and biological evaluation of PROTACs as anti-cancer agents" (H2020) focus on the development of novel E3 ligase ligands beyond Cereblon (CRBN) and VHL.

Analytical techniques used in PROTAC research include AlphaScreen®, TR-FRET (fluorescence resonance energy transfer), and NanoBRETTM as a luminescence method. Real-time monitoring of the ubiquitin conjugation and deconjugation phases is possible using the UbiReal test principle as a high-throughput screening method.

Because PROTACs act through degradation rather than inhibition, their effects can be more sustained, as the cell must synthesize new protein molecules to restore function. This precise targeting underlies the therapeutic promise of PROTACs and distinguishes them from conventional cancer therapies that often affect both diseased and normal cells. Targeted protein degradation will become a cornerstone of personalized cancer therapy.